Biosimilars are a prescription for better health.
Biosimilars could lead to over $54 billion in savings over the next ten years, giving 1.2 million patients access to needed medicines.
Join AAM and its Biosimilars Council on May 26-27, 2021 for the industry’s largest virtual conference. Access! convenes business leaders in the generics and biosimilars industry to get the inspiration, ideas and connections they need to drive their business forward.
JUST ANNOUNCED: Guest speaker Adam Fein, PhD, will be at Access! 2021 discussing the evolution and disruption in generic and biosimilar drug channels.
Roadmaps for Ensuring Patient Access to Generic and Biosimilar Medicines
This paper examines the challenges to market sustainability for generic and biosimilar medicines that have cleared the regulatory and patent hurdles to obtain FDA approval and launch into the U.S. market.
Browse our Resources
Hear more from experts on the potential of biosimilars and learn about Biosimilars Council efforts to increase biosimilar access for patients.
Want to keep up-to-date?
Enter your email address below and receive the Biosimilars Bulletin – our monthly newsletter with the most recent information on biosimilars in the United States.
FDA Biosimilars Approvals
Find an up-to-date list of FDA approved biosimilars and launches.
Featured Reports & Resources
These resources provide answers around what biosimilars are, why they are important, how they can improve patient access, and how they can save the United States billions of dollars.
